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women undergoing ART. In contrast, other authors propose
that thrombophilia screening in IVF in the general population
is not cost-effective (Fa`bregues et al, 2004).
It is important to recognize that thrombosis, as a compli-
cation of ovarian stimulation or OHSS, is an increasing
problem. As the use of ART increases, the occurrence of related
thromboembolic complications must also be investigated to
determine their causes. Clearly, further research is needed to
identify women at risk and to develop adequate therapeutic
and prophylactic measures.
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IPO-trimethylation of histone H3-lysine9 associated with P210
BCR-ABL tyrosine kinase of chronic myeloid leukaemia
BCR-ABL is the molecular hallmark and the causative event of
chronic myeloid leukaemia (CML). Deregulated proliferation
and extended survival of leukaemic progenitors are mostly
driven by multiple interactions of its p210 kDa protein tyrosine
kinase (TK) with downstream signalling pathways (Melo &
Deininger, 2004). However, the regulatory mechanisms of
BCR-ABL expression remain elusive. Gene transcription is
governed by covalent post-translational modifications of core
histone N-terminal residues (including acetylation, methyla-
tion and phosphorylation) that provide binding platforms for
specific regulatory proteins of DNA-mediated events. Accord-
ingly, enzymes that catalyse those modifications, including
histone acetyl-transferases (HDACs) and histone methyl-
transferases (HMTs), have a key role in transcriptional
repression or activation. We recently demonstrated that BCR-
ABL expression was regulated by global lysine (K) hyper-
acetylation and K20 ipo-trimethylation associated with p210 TK
(Brusa et al, 2006). Previous studies showed that H4-K20
trimethylation was preceded by H3-K9 trimethylation induced
by a specific HMT, SUV39H1, contributing with HDAC1, 2
and 3 to heterochromatin protein 1 (CBX5, HP1) recruitment
to chromatin and transcriptional repression (Schotta et al,
2004; Stewart et al, 2005). The present study aimed to elucidate
the impact of p210 BCR-ABL TK activity on H3-K9 methyl-
ation status. To this purpose, we used a 32D cell clone (8B)
expressing a temperature sensitive (ts) BCR-ABL construct
(whose proteins shows TK activity at the optimum temperature
of 33C, but not at the non-optimum temperature of 39C) and
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Fig 1. H3-K9 ipo-trimethylation associated with p210 BCR-ABL TK arises from the cytoplasmatic compartmentalization of SUV39H1 bound to the
fusion protein. (A) The impact of p210 BCR-ABL TK on H3-K9 methylation status and SUV39H1 subcellular location was investigated in 32D cell
clone (8B) stably transduced with a ts BCR-ABL mutant construct kept at the optimum (33C) temperature for fusion protein TK activity and in
K562 cell line. Parental 32D cell line and clone 8B kept at the non permissive temperature (39C) served as controls for lacking BCR-ABL expression
and p210 TK activity, respectively. (B) Cross spectrum (CS) between p210 BCR-ABL and SUV39H1. The abscissa axis indicates the frequencies from
the Fourier transform of the sequence of electron-ion interaction potential corresponding to the amino-acid sequence of the protein. The ordinate
axis indicates the amplitudes (in arbitrary units) corresponding to each frequency component in the spectrum. The dashed line represents positive
control value. (C) PCR amplification of a BCR promoter region critical for BCR-ABL transcription performed on DNA from anti-SUV39H1 ChIP
products of K562 cell line provides evidence for SUV39H1 recruitment at BCR promoter between 2 and 24 h of exposure to 1 lmol/l imatinib
mesylate (IM). The constitutively acetylated promoter of human histone H4a (region )40 to +285) was used as internal control for the amplification
reaction. D-BCR-ABL expression in K562 cell line was measured by competitive PCR. The ordinate axis indicates the number of BCR-ABL transcript
molecules/microg total RNA. The housekeeping gene (GAPDH) did not exhibit any difference relative to p210 BCR-ABL TK activity (data not
shown).
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K562 cell line (Campanini et al, 2001). Using a highly specific
antibody (Abcam, Cambridge, UK) H3-K9 trimethylation in
clone 8B at 33C was shown to be significantly lower compared
to the 32D parental cell line (not expressing BCR-ABL1) and
clone 8B at 39C (lacking p210 TK activity) (Fig 1A). Exposure
of clone 8B at 33C and K562 to the TK inhibitor Imatinib
mesylate (IM at 1 lmol/l concentration) induced a significant
and persistent increase of H3-K9 trimethylation, confirming
H3-K9 ipo-trimethylation association with p210 BCR-ABL TK
activity (Fig 1A).
H3-K9 ipo-trimethylation results from SUV39H1 ‘loss
of function’ due to its improper subcellular location. Co-immu-
noprecipitation/immunoblotting experiments using anti-ABL
SH2 and anti-SUV39H1 antibodies [from Upstate Biotechnol-
ogy (Lake Placid, NY,USA) and Santa Cruz Biotech (Santa Cruz,
CA, USA) respectively] showed that SUV39H1 was confined to
the cytoplasm bound to p210 BCR-ABL TK (Fig 1A). Its nuclear
importation both in clone 8B at 33C and K562 followed p210
BCR-ABL de-phosphorylation in response to IM exposure
(Fig 1A).Within the nucleus SUV39H1was coupled toHDAC1,
confirming the two enzyme physical interaction in a so-called
‘histone deacetylase complex’ (Fig 1A) (Vaute et al, 2002).
The informational spectrum method (ISM) is a virtual
spectroscopy method for protein structural and functional
analyses (see Supplementary material for details), which
identified one dominant peak in the cross-spectrum (CS) of
p210 BCR-ABL and SUV39H1 at 0Æ293 Fourier frequency,
confirming the two protein mutual interaction (Fig 1B)
(Veljkovic et al, 2007). In silico peptide mapping provided
evidence for the involvement of SUV39H1 SET domain in
p210 BCR-ABL interaction. Notably, the SUV39H1 N-termi-
nus domain required for the enzyme interaction with HDAC1
does not participate in its ligand binding to p210 BCR-ABL TK
(see Fig S1 and S2) (Vaute et al, 2002).
The putative role of SUV39H1 recruitment to chromatin in
BCR-ABL transcription was investigated in K562 cells, where
BCR-ABL expression is under the control of BCR promoter
(ts BCR-ABL expressed through transfection in clone 8B is
under the control of an heterologous promoter: The myelo-
proliferative sarcoma virus LTR promoter). Polymerase chain
reaction (PCR) amplification of DNA from chromatin
immuno-precipitation products (ChIP) with the anti-
SUV39H1-ChIP grade antibody (Upstate Biotechnology)
demonstrated that SUV39H1 was recruited at a BCR promoter
critical for BCR-ABL transcription after p210 BCR-ABL TK
inhibition by IM (Fig 1C). SUV39H1 tethering to chromatin is
expected to repress transcription through mechanisms involv-
ing CBX5 (HP1) stable recruitment to trimethylated H3-K9
and histone deacetylation (Stewart et al, 2005). Accordingly,
the number of BCR-ABL transcript molecules (quantified by
mean of a previously published competitive PCR strategy)
underwent a significant reduction between 2 and 24 h of IM
exposure (Fig 1D) (Brusa et al, 2006).
H3-K9 methylation status and SUV39H1 subcellular loca-
tion relative to BCR-ABL expression were further investigated
in early myeloid progenitors (CD34+) obtained from bone
marrow samples of six CML patients at diagnosis and
peripheral blood apheresis of two haematologically normal
persons intended for autologous transplantation after
informed consent. Preliminary experiments (not shown) did
not determine differences in histone acetylation and methyl-
ation patterns and BCR-ABL expression relative to CD34+
source in CML patients. CD34+ cell concentration following
immuno-magnetic sorting was 95% or greater and more than
80% of CD34+ cells from CML patients harboured BCR-ABL1,
based on fluorescence in situ hybridization analysis, and
expressed the p210 fusion protein (data not shown and
Fig 2A). H3-K9 trimethylation was significantly lower in
CD34+ cells from four CML patients compared to CD34+
normal subjects and completely absent in the other two
(Fig 2A). Moreover, SUV39H1 was undetectable in the nuclear
compartment of CD34+ cells from all CML patients: It was
located in the cytoplasm bound to p210 BCR-ABL (Fig 2A).
Further investigation is required to elucidate whether H3-K9
tri-methylation, still apparent in CD34+ cells of CML patients
2, 3, 5 and 6 in spite of SUV39H1 absence in the nuclear
compartment, arises from enzymatic activities of other HMTs
involved in H3-K9 trimethylation, including SUV39H2 and
ESET/SETDB1 (Kouzarides, 2007). PCR amplification per-
formed on DNA from anti-SUV39H1 ChIP products of two
CML patients (patients 1 and 2) and normal persons
confirmed that, in BCR-ABL-expressing CD34+ cells,
SUV39H1 is not recruited to the BCR promoter (Fig 2B).
In conclusion, our work confirms an epigenetic control of
BCR-ABL expression involving H3-K9 ipo-trimethylation as a
(A)
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Fig 2. H3-K9 trimethylation status and SUV39H1 subcellular location
in early CD34+ haematopoietic progenitors. (A) CD34+ cells were
purified from bone marrow samples of six CML patients at diagnosis
and peripheral blood aphaeresis of two haematologically normal per-
sons (intended for bone marrow transplantation) after informed
consent. Eighty per cent or more of CD34+ cells from CML patients
exhibited BCR-ABL based on FISH analysis (data not shown). (B) PCR
amplification of a BCR promoter region critical for BCR-ABL tran-
scription performed on DNA from anti-SUV39H1 ChIP products of
CD34+ from CML patients no. 1 and 2 and normal controls. See legend
to Fig 1 for details.
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result of SUV39H1 cytoplasmatic compartmentalization by
p210 BCR-ABL TK.
SUV39H1 associationwithHDAC1, following its release from
the cytoplasmatic ligand to p210 BCR-ABL fusion protein TK
and nuclear import in response to IM, may reinforce the
repressive chromatin state and influence BCR-ABL expression.
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Supplementary material
The following supplementary material is available for this
article online:
Fig S1. CS between p210 BCR-ABL TK and SUV39H1-
nSET; the abscissa axis indicates the frequencies from the
Fourier transform of the sequence of electron–ion interaction
potential corresponding to the amino-acid sequence of the
protein.
Fig S2. CS between p210 BCR-ABL TK and SUV39H1-
nN180. See legend to Fig S1 for details.
The material is available as part of the online article from:
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.
2008.07134 (This link will take you to the article abstract).
Please note: Blackwell Publishing are not responsible for the
content or functionality of any supplementary materials sup-
plied by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
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JAK2 V617F mutation is associated with increased risk of
thrombosis in Chinese patients with essential
thrombocythaemia
Essential thrombocythaemia (ET) is a Philadelphia-chromo-
some–negative myeloproliferative disorder (MPD) character-
ized by persistent thrombocytosis, excessive proliferation of
megakaryocytes in the bone marrow, normal erythrocytic
mass, and the absence of prominent bone marrow fibrosis. The
JAK2 V617F mutation, caused by a G>T transversion in exon
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